Role of aliskiren in blood pressure control and renoprotection

References

• KearnyPMWheltonMReynoldsKGlobal burden of hypertension: analysis of worldwide dataLancet200536521722315652604
   PubMed Web of Science ®Google Scholar
• RitzEHypertension. The kidney is the culprit even in the absence of kidney diseaseKidney Int20077137137217315002
   PubMed Web of Science ®Google Scholar
• LevingtonSClarkeRQizilbashNAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesLancet20023601903191312493255
   PubMed Web of Science ®Google Scholar
• United States Renal Data System 2010 Annual Data Report, CD Vol 1, Chapter 1, Table ei, page 48.
   Google Scholar
• United States Renal Data System 2010 Annual Data Report, CD Vol 1, Chapter 2, Table 19i, page 61.
   Google Scholar
• United States Renal Data System 2010 Annual Data Report, CD Vol 2, Chapter 2, Table 2 10ii, page 258.
   Google Scholar
• BakrisGLSlowing nephropathy progression: focus on proteinuria reductionClin J Am Soc Nephrol20083Suppl 1S3S1018178794
   PubMed Web of Science ®Google Scholar
• PetersonJCAdlerSBurkartJMBlood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease StudyAnn Int Med19951237547627574193
   PubMed Web of Science ®Google Scholar
• De ZeewDRemuzziGParvingHHProteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy:Lessons from RENAALKidney Int2004652309232015149345
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRSeventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension2003421206125214656957
   PubMed Web of Science ®Google Scholar
• BakrisGLWilliamsMDworkinLPreserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working GroupAm J Kidney Dis20003664666110977801
   PubMed Web of Science ®Google Scholar
• De ZeewDRemuzziGParvingHHAlbuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathyCirculation200411092192715302780
   PubMed Web of Science ®Google Scholar
• KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney diseaseAm J Kidney Dis200749Suppl 2S1S179
   PubMed Web of Science ®Google Scholar
• GargJPBakrisGLMicroalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular diseaseVasc Med20027354312083733
   PubMed Web of Science ®Google Scholar
• ManciaGDe BackerGDominiczakA2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens2007251105118717563527
   PubMed Web of Science ®Google Scholar
• LinasSLAre two better than one? Angiotensin converting enzyme inhibitors plus angiotensin receptor blockers for reducing blood pressure and proteinuria in kidney diseaseClin J Am Soc Nephrol20083SupplS17S2318178792
   PubMed Web of Science ®Google Scholar
• AziziMMenardJCombined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonistsCirculation20041092492249915173039
   PubMed Web of Science ®Google Scholar
• MooserVNussbergerJJullieratLReactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibitionJ Cardiovasc Pharmacol1990152762821689424
   PubMed Web of Science ®Google Scholar
• HollenbergNKFisherNDPriceDAPathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin systemHypertension1998323873929740600
   PubMed Web of Science ®Google Scholar
• WolnyAClozelJPReinJFunctional and biochemical analysis of angiotensin II-forming pathways in the human heartCirc Res1997802192279012744
   PubMed Web of Science ®Google Scholar
• FisherNDLAllanDKiforIResponses of converting enzyme and renin inhibition: role of angiotensin II in humansHypertension19942344518282330
   PubMed Web of Science ®Google Scholar
• JeunemaitreXMenardJNussbergerJPlasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560 A in hypertensive patientsAm J Hypertens198928198272686709
   PubMed Web of Science ®Google Scholar
• RahuelJRasettiVMaibaumJStructure-based drug design: the discovery of novel non-peptide orally active inhibitors of human reninChem Biol2000749350410903938
   PubMed Web of Science ®Google Scholar
• GradmanAHSchimiederRELinsRLAliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patientsCirculation20051111012101815723979
   PubMed Web of Science ®Google Scholar
• TrimarchiHOriasMAliskiren and the kidney: beyond hypertensionNephrology Reviews20091e1e4
   Google Scholar
• WoodJMMaibaumJRahuelJStructure-based design of aliskiren, a novel orally effective renin inhibitorBiochem Biophys Res Commun200330869870512927775
   PubMed Web of Science ®Google Scholar
• NguyenGDelarueFBurckleCPivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to reninJ Clin Invest20021091417142712045255
   PubMed Web of Science ®Google Scholar
• FeldtSBatenburgWWMazakIProrenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptideHypertension20085168268818212269
   PubMed Web of Science ®Google Scholar
• DeinumJRonnBMathiesenEIncrease in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitusDiabetologia1999421006101010491762
   PubMed Web of Science ®Google Scholar
• ChiarelliFPomilioMDe LucaFAPlasma prorenin levels may predict persistent microalbuminuria in children with diabetesPediatr Nephrol20011611612011261677
   PubMed Web of Science ®Google Scholar
• NguyenGDelarueFBurckleCPivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to reninJ Clin Invest20021091417142712045255
   PubMed Web of Science ®Google Scholar
• HuangYWongamornthamSKastingJRenin increases mesangial cell transforming growth factor beta and matrix proteins through receptor-mediated, angiotensin II-independent mechanismsKidney Int20066910511316374430
   PubMed Web of Science ®Google Scholar
• BenedictCRJohnstoneDEWeinerDHRelation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular DysfunctionJ Am Coll Cardiol199423141014207909822
   PubMed Web of Science ®Google Scholar
• KehoeBKeetonGRHillCElevated plasma renin activity associated with renal dysfunctionNephron19864451573528881
   PubMed Web of Science ®Google Scholar
• BrunnerHRLaraghJHBaerLEssential hypertension: renin and aldosterone, heart attack and strokeN Engl J Med19722864414494257928
   PubMed Web of Science ®Google Scholar
• NovartisTekturna (aliskiren) tablets 150 mg and 300 mg: US prescribing informationEast Hanover (NJ)Novartis Pharmaceuticals Corporation http://www.pharma.us.novartis.com/product/pi/pdf/tekturna.pdf. Accessed March 4, 2011.
   Google Scholar
• VaidyanathanSJarugulaVDieterichHAClinical pharmacokinetics and pharmacodynamics of aliskirenClin Pharmacokinet20084751553118611061
   PubMed Web of Science ®Google Scholar
• AziziMMenardJBisseryAPharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruptionJ Am Soc Nephrol2004153126334515579516
   PubMed Web of Science ®Google Scholar
• VaidyanathanSCamenischGSchuetzHPharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskirenJ Clin Pharmacol2008481323133818784280
   PubMed Web of Science ®Google Scholar
• VaidyanathanSJarugulaVDieterichHAClinical pharmacokinetics and pharmacodynamics of aliskirenClin Pharmacokinet20084751553118611061
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyRasilez: summary of product characteristics http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000780/WC500047010.pdf. Accessed March 4, 2011.
   Google Scholar
• ZhaoCVaidyanathanSYehCMAliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitusClin Pharmacokinet2006451125113417048976
   PubMed Web of Science ®Google Scholar
• WaldmeierFGlaenzelUWirzBAbsorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteersDrug Metab Dispos2007351418142817510248
   PubMed Web of Science ®Google Scholar
• VaidyanathanSZhaoCYehCPharmacokinetics and safety of the novel oral renin inhibitor aliskiren in patients with type 2 diabetesClin Pharmacol Ther200579SupplS12
   Google Scholar
• BartlettMVaidyanathanSKaranRSMultiple dose pharmacokinetics of the direct renin inhibitor aliskiren in healthy Chinese subjectsClin Pharmacol Ther200883Suppl 1S61S62
   Google Scholar
• VaidayanathanSJermanyJYehCAliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjectsBr J Clin Pharmacol20066269069817118124
   PubMed Web of Science ®Google Scholar
• DieterichHAYehCHowardDAssessment of the pharmacokinetic interaction between the oral direct renin inhibitor aliskiren and furosemide: a study in healthy volunteers [abstract no. PIII-78]Clin Pharmacol Ther200781Suppl 1S110
   Google Scholar
• TapaninenTNeuvonenPJNiemiMRifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskirenEur J Clin Pharmacol20106649750220179914
   PubMed Web of Science ®Google Scholar
• NguyenGDelarueFBurckleCPivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to reninJ Clin Invest20021091417142712045255
   PubMed Web of Science ®Google Scholar
• CampbellDJInterpretation of plasma renin concentration in patients receiving aliskiren therapyHypertension200851151817984367
   PubMed Web of Science ®Google Scholar
• LuftFCWinbergerMHAntihypertensive therapy with aliskirenKidney Int20087367968318160962
   PubMed Web of Science ®Google Scholar
• OparilSYarowsSAPatelSEfficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trialLancet200737022122917658393
   PubMed Web of Science ®Google Scholar
• NguyenGThe (pro)renin receptor:pathophysiological roles in cardiovascular and renal pathologyCurr Opin Nephrol Hypertens20071612913317293688
   PubMed Web of Science ®Google Scholar
• SealeyJELaraghJHAliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its affectivenessAm J Hypertens20072058759717485026
   PubMed Web of Science ®Google Scholar
• NussbergerJAubertJFBouzoureneKRenin inhibition by aliskiren prevents atherosclerosis progression. Comparison with irbesartan, atenolol, and amlodipineHypertension2008511306131118391092
   PubMed Web of Science ®Google Scholar
• BenedictCRJohnstoneDEWeinerDHRelation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular DysfunctionJ Am Coll Cardiol199423141014207909822
   PubMed Web of Science ®Google Scholar
• KehoeBKeetonGRHillCElevated plasma renin activity associated with renal dysfunctionNephron19864451573528881
   PubMed Web of Science ®Google Scholar
• BrunnerHRLaraghJHBaerLEssential hypertension: renin and aldosterone, heart attack and strokeN Engl J Med19722864414494257928
   PubMed Web of Science ®Google Scholar
• FisherNDHollenbergMKRenin inhibition: what are the therapeutic opportunities?J Am Soc Nephrol20051659259915703270
   PubMed Web of Science ®Google Scholar
• RichterWFWhitbyBRChouRCDistribution of remikiren, a potent orally active inhibotor of human renin, in laboratory animalsXenobiotica1996262432548730917
   PubMed Web of Science ®Google Scholar
• FeldmanDLPersohnESchitzHRenal localization of the renin inhibitor aliskirenJ Clin Hypertens20068Suppl AA80
   Google Scholar
• DugganSTChwiedukCMCurranMPAliskiren. A review of its use as monotherapy and as combination therapy in the management of hypertensionDrugs2010702011104920883056
   PubMed Web of Science ®Google Scholar
• OhBHMitchellJHerronJRAliskiren, an oral rennin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertensionJ Am Coll Cardiol2007491157116317367658
   PubMed Web of Science ®Google Scholar
• OparilSYarowsSAPatelSEfficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised double-blind trial [published erratum appears in Lancet. 2007;370(9598):1542]Lancet200737022122917658393
   PubMed Web of Science ®Google Scholar
• VillamilAChrysantSGCalhounDRenin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazideJ Hypertens20072521722617143194
   PubMed Web of Science ®Google Scholar
• KushiroTItakuraHAboYAliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertensionHypertens Res200629997100517378372
   PubMed Web of Science ®Google Scholar
• GradmanAHSchmiederRELinsRLAliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patientsCirculation20051111012101815723979
   PubMed Web of Science ®Google Scholar
• WeirMRPrescottMFBushCAntihypertensive efficacy of the direct renin inhibitor aliskiren in patients with diabetes, metabolic syndrome or obesity: a pooled analysis of 10 randomized trials [abstract no. P888]Circulation2008118162
   Web of Science ®Google Scholar
• AndersenKWeinbergerMHEganBComparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trialJ Hypertens20082658959918300872
   PubMed Web of Science ®Google Scholar
• SchmiederREPhilippTGuerediagaJLong-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazideCirculation200911941742519139391
   PubMed Web of Science ®Google Scholar
• KroneWHanefeldMMeyerH-FComparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndromeJ Hum Hypertens20112518619520376075
   PubMed Web of Science ®Google Scholar
• PoolJLSchmiederREAziziMAliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartanAm J Hypertens200720112017198906
   PubMed Web of Science ®Google Scholar
• StantonAJensenCNussbergerJBlood pressure lowering in essential hypertension with an oral renin inhibitor, aliskirenHypertension2003421137114314597641
   PubMed Web of Science ®Google Scholar
• DietzRDechendRYuCMEffects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertensionJ Renin Angiotensin Aldosterone Syst2008916317518957387
   PubMed Web of Science ®Google Scholar
• BlackHRKribbenAAguirre PalaciosFAliskiren as monotherapy or in combination with hydrochlorothiazide provides effective BP lowering in patients with systolic BP 160 ≤ 180 mm Hg (ACQUIRE study) [abstract no. PO-15]J Clin Hypertens201012Suppl 1A24
   Google Scholar
• ChrysantSGMurrayAVHoppeUCLong-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysisCurr Med Res Opin2008241039104718307835
   PubMed Web of Science ®Google Scholar
• LittlejohnTW3rdTrenkwalderPHollandersGLong-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertensionCurr Med Res Opin20092595195919257800
   PubMed Web of Science ®Google Scholar
• GeigerHBarrancoEGorostidiMCombination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide aloneJ Clin Hypertens200911324332
   PubMed Web of Science ®Google Scholar
• JordanJEngeliSBoyeSWDirect renin inhibition with aliskiren in obese patients with arterial hypertensionHypertension2007491047105517353513
   PubMed Web of Science ®Google Scholar
• BasileJBabazadehSLillestolMFirst-line aliskiren/hydrochlorothiazide combination treatment lowers BP more effectively than hydrochlorothiazide alone in older patients with stage 2 hypertension (ACTION study) [abstract no. PO-11]J Clin Hypertens201012Suppl 1A22
   Google Scholar
• FerdinandKPoolJWeitzmanRResponses to aliskiren/HCTZ versus amlodipine on peripheral and central blood pressure in African American patients with stage 2 hypertensionJ Am Coll Cardiol20105510 Suppl 1A61.E586
   Google Scholar
• ZieveFYadaoAYurkovicCAliskiren with or without hydrochlorothiazide lowers blood pressure effectively in patients with stage 2 hypertension and metabolic syndrome [abstract no. PP.38.505]J Hypertens201028Suppl Ae600
   Google Scholar
• TownsendRRForkerARumpeltPInitial combination therapy with aliskiren/hydrochlorothiazide is more effective than amlodipine in patients with stage 2 systolic hypertension and diabetes mellitus [abstract no. LB-PO-03]J Clin Hypertens201012534
   Google Scholar
• UresinYTaylorAAKiloCEfficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertensionJ Renin Angiotensin Aldosterone Syst2007819019818205098
   PubMed Web of Science ®Google Scholar
• Braun-DullaeusRCZhangJHristoskovaSFirst line therapy with aliskiren/amlodipine combination provides robust blood pressure reductions in patients with moderate to severe hypertension [abstract no. PO-22]J Clin Hypertens201012Suppl 1A27
   Google Scholar
• BlackHWeinbergerMPurkayasthaDCombination aliskiren/amlodipine is more effective than amlodipine monotherapy in male and female African American subjects with stage 2 hypertension [abstract no. PO-20]J Clin Hypertens201012Suppl 1A26
   Google Scholar
• DietzRDechendRYuCMEffects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertensionJ Renin Angiotensin Aldosterone Syst2008916317518957387
   PubMed Web of Science ®Google Scholar
• ParvingHHPerssonFLewisJBAliskiren combined with losartan in type 2 diabetes and nephropathyN Engl J Med20083582433244618525041
   PubMed Web of Science ®Google Scholar
• SolomonSDAppelbaumEManningWJEffect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophyCirculation200911953053719153265
   PubMed Web of Science ®Google Scholar
• McMurrayJJVPittBLatiniREffects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failureCirc Heart Fail20081172419808266
   PubMed Web of Science ®Google Scholar
• SciricaBMMorrowDABodeCPatients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 TrialEur Heart J2010311993200520558431
   PubMed Web of Science ®Google Scholar
• ClelandJGFColettaAPBugaLClinical trials update from the American College of Cardiology meeting 2010: DOSE, ASPIRE, CONNECT, STICH, STOPAF, CABANA, RACE II, EVEREST II, ACCORD, and NAVIGATOREur J Heart Fail20101262362920498271
   PubMed Web of Science ®Google Scholar
• Novartis Six months efficacy and safety of aliskiren therapy on top of standard therapy, on morbidity and mortality in patients with acute decompensated heart failure (ASTRONAUT) [ClinicalTrialsgov identifier NCT00894387]US National Institutes of Health http://www.clinicaltrials.gov. Accessed March 4, 2011.
   Google Scholar
• Novartis Aliskiren trial in type 2 diabetes using cardiovascular and renal disease endpoints (ALTITUDE) [ClinicalTrialsgov identifier NCT00549757]US National Institutes of Health http://www.clinicaltrials.gov. Accessed March 4, 2011.
   Google Scholar
• Novartis Efficacy and safety of aliskiren and aliskiren/enalapril combination on morbi-mortality in patients with chronic heart failure (ATMOSPHERE) [ClinicalTrialsgov identifier NCT00853658]US National Institutes of Health http://www.clinicaltrials.gov. Accessed March 4, 2011.
   Google Scholar